TG Therapeutics ((TGTX)) has held its Q3 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TG Therapeutics recently held an earnings call that conveyed a predominantly positive sentiment, underscored by robust financial performance and promising clinical developments. Despite some challenges, such as increased operating expenses and limited international sales growth, the highlights of the call significantly outweighed the lowlights, reflecting a strong quarter for the company.
Strong Financial Performance
The company reported total revenue of $161.7 million, marking a 93% increase compared to the third quarter of 2024 and a 15% rise over the second quarter of 2025. U.S. BRIUMVI net sales in the third quarter were approximately $153 million, surpassing both internal targets and market expectations, showcasing the product’s strong market performance.
Positive Clinical Developments
TG Therapeutics highlighted the swift completion of enrollment for the ENHANCE study, indicating strong interest in their clinical trials. The Phase III subcutaneous ublituximab study is progressing well, with potential approval and launch anticipated in 2028, further bolstering the company’s clinical pipeline.
Share Repurchase Program
The company successfully completed an initial $100 million share repurchase program, buying back 3.5 million shares. Additionally, TG Therapeutics has authorized another $100 million share repurchase program, reflecting confidence in its financial health and commitment to returning value to shareholders.
Sustained Demand and Market Expansion
The CD20 class, which includes BRIUMVI, now represents nearly $10 billion in annual U.S. MS sales. BRIUMVI’s market presence has expanded significantly, with new prescribers and accounts contributing to its growing demand and market footprint.
Raised Full-Year Revenue Guidance
TG Therapeutics has increased its full-year 2025 U.S. BRIUMVI net revenue guidance to approximately $585 million. This upward revision reflects the strong demand trends and the company’s confidence in its continued market success.
Increased Operating Expenses
The company reported an increase in total operating expenses compared to the second quarter of 2025. This rise was primarily attributed to investments in research and development for subcutaneous BRIUMVI and higher spending on sales, general, and administrative expenses.
Limited Ex-U.S. Sales
Despite the strong performance in the U.S., TG Therapeutics reported ex-U.S. sales of only $6.4 million, highlighting limited expansion outside the domestic market. This remains an area for potential growth and strategic focus.
Forward-Looking Guidance
TG Therapeutics provided comprehensive guidance on its financial outlook and product development. The company anticipates continued strong performance, with U.S. net sales for BRIUMVI expected to reach approximately $585 million for the full year 2025. Ongoing pivotal studies, including the ENHANCE trial and the Phase III subcutaneous ublituximab study, are on track, with significant milestones expected in the coming years.
In summary, TG Therapeutics’ earnings call painted a picture of a company on a strong growth trajectory, driven by impressive financial results and promising clinical advancements. While challenges such as increased operating expenses and limited international sales persist, the overall sentiment remains positive, with the company well-positioned for future success.